Roche moves ahead on two fronts.
The ACCU-CHEK Nano meter, part of the ACCU-CHEK Nano SmartView System, is said to offer such enhanced features as ease-of-use; fast and accurate readings; and small, portable size. Moreover, the meter offers patients the flexibility to test at anytime--day or night--with a prominent backlit display.
Diabetes affects 25.8 million children and adults in the United States; approximately one in 12 people. Regular and accurate monitoring of blood glucose levels through self-testing is essential to managing the disease and can reduce the risk of diabetes-related complications such as heart disease, stroke, kidney failure, nerve damage or blindness,
An accurate blood glucose reading can help to inform a patient's food choice, insulin use and lifestyle habits.
The ACCU-CHEK Nano SmartView system offers advanced accuracy as tested against a 23% tighter specification--greater than the current standard that is set by the International Organization for Standardization (ISO).
Testing with the meter requires only a small drop of blood (0.6 microliters) and provides a blood glucose reading within five seconds.
"We are pleased to offer an innovative, user-friendly blood glucose meter that can be easily integrated into the lives of people with diabetes," said Marc Gibeley, head of Roche Diabetes Care North America. "It is a smaller, sleeker option in our broad portfolio of ACCU-CHEK meters. For more than 35 years Roche Diabetes Care has been committed to the diabetes community, and the ACCUCHEK Nano meter builds upon that promise."
In other developments at the company, Roche reported last month that Lucentis (ranibizumab injection) was approved by the Food and Drug Administration for treatment of diabetic macular edema (DME), an eye condition in people with diabetes that causes blurred vision, severe vision loss and sometimes blindness. Diabetes is now the leading cause of new cases of blindness in American adults, and DME is estimated to affect more than 560,000 Americans who are living with the disease.
Lucentis is the first FDA-approved medicine for DME, a condition for which the standard of care has not changed significantly in more than 25 years. To date, the standard of care in the United States for DME has been laser surgery, which slows the rate of vision loss and helps stabilize vision but has demonstrated limited ability to restore lost vision.
"For the first time, Americans with diabetic macular edema will have access to an FDA-approved medicine shown to help many patients rapidly regain substantial amounts of lost vision," said Dr. Hal Barron, chief medical officer and head of global product development. "We developed Lucentis to treat diseases of the eye and are pleased to have received this third U.S. indication to help a new population of people whose eyesight ]nay be affected by diabetes."
Lucentis is marketed in the United States by Roche's Genentech unit and was first approved in 2006 to treat a form of macular degeneration. According to reports, Roche recorded about $1.7 billion worth of Lucentis sales in the U.S. last year. Novartis AG sells the drug outside the U.S.
The FDA approved a 0.3 milligram dose of the product, which Genentech said would cost $1,170. The approval was expected after an FDA panel of nonagency medical experts unanimously voted that Lucentis was effective at treating diabetic macular edema.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||RX/Diabetes Care|
|Publication:||Chain Drug Review|
|Date:||Sep 24, 2012|
|Previous Article:||Nipro, NextGen team up.|
|Next Article:||Community pharmacists take on a bigger role.|